Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma is also known as transitional cell carcinoma. Bladder transitional cell carcinoma (TCC) is the most common tumor of the entire urinary system and TCC is the most common primary neoplasm of the urinary bladder. Cancer of the ureter may not have symptoms in the early stages of the disease. However, symptoms may appear as the cancer grows. These include: persistent back pain, blood in the urine, painful or frequent urination, fatigue unexplained weight loss. These symptoms are associated with malignant cancer of the ureter and other health conditions. 

The treatment of Urothelial carcinoma involves surgery, chemotherapy and radiotherapy. The tests to diagnose Urothelial carcinoma includes Urine tests, Ureteroscopy, Intravenous pyelogram (IVP), Retrograde pyelography, CT scan, MRI scan and Chest X-ray. While the treatment with surgery include open surgery, laparoscopic surgery and percutaneous endoscopic surgery. Chemotherapy treatment usually involves the treatment with a combination of drugs. The combinations includes: gemcitabine and cisplatin, gemcitabine and carboplatin as well as methotrexate, vinblastine, doxorubicin and cisplatin. Radiotherapy is not frequently used for transitional cell carcinoma of the kidney or ureter. Patient may have radiotherapy to the area of the ureter or kidney if patients are not fit enough to have an operation or cancer has spread into surrounding tissue.

The Urothelial carcinoma market has been segmented by type of drugs, by end-user and by geography. The type of drugs sub-segmented as targeted and chemotherapy. The drugs like Levatinib, Atezolizumab, Nivelumab, Enzalutamide, Abiraterone acetate, Cabazitaxel, sipuleucel-T, everolimus, bevacizumab and pazopanib are used in treatment of Urothelial carcinoma. The end-users for the Urothelial carcinoma market include Hospitals, Specialty Clinics, Cancer Research Institutes and Ambulatory Surgical Centers.

Belgium holds the top rank in incidences of bladder cancer, which is followed by Lebanon and Malta. Bladder cancer cases occur in more developed countries, notably around 59%. The regions like Northern America and Europe having highest incidence of bladder cancer; and Asia, Latin America and the Caribbean having the lowest incidence. Transitional cell cancer develops in the part of the kidney called the renal pelvis. Transitional cell cancers are rare and only about 7 out of 100 kidney cancers (7%) diagnosed in the UK. The most common type of kidney cancer is renal cell cancer. Transitional cell cancer of the ureter is even more infrequent than transitional cell cancer of the kidney. TCC of the kidney is 4 times more common than cancer of the ureter. The most common type of bladder cancer is transitional cell cancers of the bladder. According to the estimation of American Cancer Society for bladder cancer, in 2016 there would be about 76,960 new cases of bladder cancer, and about 16,390 deaths from bladder cancer alone in the United States. In recent years the rates of cancer deaths and new bladder cancers have been dropping slightly in women. Incidence rates have been decreasing and death rates have been stable in men. About 5% of all newly diagnosed cancers in the US are Bladder cancers. It is the fourth most frequent cancer in men, but it is not common in women.

The major players operating in Urothelial carcinoma market include Genentech, GlaxoSmithKline, Genentech, Novartis, Dendreon, Sanofi Aventis, Bristol-Myers Squibb and Eisai are among other significant players worldwide.

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.

All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

  • Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
  • Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
  • Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
  • Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to

  • North America, South America, and the Americas
  • Asia Pacific and Japan
  • Europe
  • Latin America
  • Middle East and Africa

The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:

  • What are the major recent trends that can influence the product life cycle and the RoI?
  • Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
  • Which micromarketing initiatives of leading players will bring in investments?
  • What can be the best framework and tools for PESTLE analysis?
  • Which regions will witness rise in new opportunities?
  • Which are the game-changing technologies being used to capture new revenue streams in the near future?
  • Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
  • What is the current and expected intensity of competition the market in the near future?

Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Urothelial Carcinoma Treatment Market